Patterns of use of prophylaxis for stress-related mucosal disease in patients admitted to the intensive care unit

Journal of Intensive Care Medicine

Volumn 29, Issue 2, 2014, Pages 96-103

  Frandah, Wesam ^a   Colmer Hamood, Jane ^b   Nugent, Kenneth ^a   Raj, Rishi ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

intensive care; prophylaxis; proton pump inhibitors; stress ulcers; use patterns

Indexed keywords

ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; SUCRALFATE;

ADULT; AGED; ARTICLE; FEMALE; GASTRITIS; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; STOMACH MUCOSA LESION; STOMACH ULCER; STRESS ULCER; VERY ELDERLY; YOUNG ADULT;

INTENSIVE CARE; PROPHYLAXIS; PROTON PUMP INHIBITORS; STRESS ULCERS; USE PATTERNS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; APACHE; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PATIENT ADMISSION; PROSPECTIVE STUDIES; RISK FACTORS; STRESS, PSYCHOLOGICAL; TERTIARY CARE CENTERS; TEXAS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896140630     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066612453542     Document Type: Article

References (36)

1. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994 ; 330 (6). 377-381
2. Cook DJ, Griffith LE, Walter SD, et al. Canadian Critical Care Trials Group. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care. 2001 ; 5 (6). 368-375
3. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011 ; 183 (3). 310-319
4. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm. 1999 ; 56 (4). 347-379
5. ASHP. http://www.ashp.org/Import/PRACTICEANDPOLICY/ PolicyPositionsGuidelinesBestPractices/BrowsebyDocumentType/ TherapeuticGuidelines.aspx; Accessed on March 31, 2012.
6. Ellison RT, Perez-Perez G, Welsh CH, et al. Risk factors for upper gastrointestinal bleeding in intensive care unit patients: role of Helicobacterpylori. Federal Hyperimmune Immunoglobulin Therapy Study Group. Crit Care Med. 1996 ; 24 (12). 1974-1981
7. Fusamoto H, Hagiwara H, Meren H, et al. A clinical study of acute gastrointestinal hemorrhage associated with various shock states. Am J of Gastroenterol. 1991 ; 86 (4). 429-433
8. Czaja AJ, McAlhany JC, Pruitt BA.. Acute gastroduodenal disease after thermal injury. An endoscopic evaluation of incidence and natural history. N Engl J Med. 1974 ; 291 (18). 925-929
9. Brown TH, Davidson PF, Larson GM. Acute gastritis occurring within 24 hours of severe head injury. Gastrointest Endosc. 1989 ; 35 (1). 37-40
10. Goodman AA, Frey CF. Massive upper gastrointestinal hemorrhage following surgical operations. Ann Surg. 1968 ; 167 (2). 180-184
11. Lucas CE, Sugawa C, Riddle J, Rector F, Rosenberg B, Walt AJ. Natural history and surgical dilemma of "stress" gastric bleeding. Arch Surg. 1971 ; 102 (4). 266-273
12. Peura DA, Johnson LF. Cimetidine for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Inter Med. 1985 ; 103 (2). 173-177
13. Poleski MH, Spanier AH. Cimetidine versus antacids in the prevention of stress erosions in critically ill patients. Am J Gastroenterol. 1986 ; 81 (2). 107-111
14. Duerksen DR. Stress-related mucosal disease in critically ill patients. Best pract Res Clin Gastroenterol. 2003 ; 17 (3). 327-344
15. Sesler JM.. Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. AACN Adv Crit Care. 2007 ; 18 (2). 119-126
16. Mutlu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. Chest. 2001 ; 119 (4). 1222-1241
17. Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. Crit Care Med. 2002 ; 30 (6 suppl). S351 - S355
18. Schuster DP, Rowley H, Feinstein S, McGue MK, Zuckerman GR. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med. 1984 ; 76 (4). 623-630
19. Yasue N, Guth PH. Role of exogenous acid and retransfusion in hemorrhagic shock-induced gastric lesions in the rat. Gastroenterology. 1988 ; 94 (5 pt 1). 1135-1143
20. Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am. 2009 ; 38 (2). 245-265
21. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996 ; 275 (4). 308-314
22. Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med. 2010 ; 38 (4). 1197-1205
23. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998 ; 338 (12). 791-797
24. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007 ; 64 (13). 1396-1400
25. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006 ; 101 (10). 2200-2205
26. Pitimana-aree S, Forrest D, Brown G, Anis A, Wang XH, Dodek P. Implementation of a clinical practice guideline for stress ulcer prophylaxis increases appropriateness and decreases cost of care. Intensive Care Med. 1998 ; 24 (3). 217-223
27. Nasser SC, Nassif JG, Dimassi HI. Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroentero. 2011; ;1 (6(8). 982-98
28. Perwaiz MK, Posner G, Hammoudeh F, et al. Inappropriate Use of Intravenous PPI for Stress Ulcer Prophylaxis in an Inner City Community Hospital. J Clin Med Res. 2010 ; 2 (5). 215-219
29. Alsultan MS, Mayet AY, Malhani AA, Alshaikh MK. Pattern of intravenous proton pump inhibitors use in ICU and Non-ICU setting: a prospective observational study. Saudi J Gastroenterol. 2010 ; 16 (4). 275-279
30. Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010 ; 103: 207-211
31. Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond. J Crit Care. 2010 ; 25 (2). 214-220
32. Wohlt PD, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother. 2007 ; 41 (10). 1611-1616
33. Schupp KN, Schrand LM, Mutnick AH. A cost-effectiveness analysis of stress ulcer prophylaxis. Ann Pharmacother. 2003 ; 37 (5). 631-635
34. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005 ; 294 (23). 2989-2995
35. Kim JW, Lee KL, Jeong JB, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010 ; 16 (28). 3573-3577
36. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 ; 32 (8). 821-827